All News
Predictors and Outcomes in Systemic Sclerosis
EurekAlert!
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.
Read Article
Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD
Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.
Read Article
Prediction of PsA in PSO pts: does it work?
First predictive model using mainly clinical data and labs extracted from primary care
Performs well in the cohort it was trained w/ but not in validation cohort.
Often an issue with prediction models!
Needs more granularity than https://t.co/5cVgqfd4fX
Aurelie Najm AurelieRheumo ( View Tweet)
Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors
The concept of D2M axSpA is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. https://t.co/KmfJvAtwp0
Dr. John Cush RheumNow ( View Tweet)
Live Daily Eular 2025 Recap Day 2 https://t.co/78NYTcFPG6
Links:
Dr. John Cush RheumNow ( View Tweet)
Secukinumab promise in PMR is real
GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj
Dr. John Cush RheumNow ( View Tweet)
What's the difference between PIPsA & NIPsA?
(Persistent Inflammatory confirmed by IMAGING
vs. Non inflammatory PsA)
🔹️Cross-sectional study
🔹️517 pts under b/tsDMARDs
🔹️10.3% D2T
🔹️57% PIPsA / 43% NIPsA
👇 Distinct phenotypes 👇
OP0176
#EULAR2025
@rheumnow https://t.co/YGHpbeE6ws
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#guidelines everywhere
@jeffsparks presents points of interest from #ACR #ILD #recommendations
- a joint venture with American College of Chest Physicians
While simultaneously the EULAR ILD recommendations are being unveiled!
@RheumNow #EULAR2025 @eular_org @ACRheum https://t.co/cfHrqIAbx9
Links:
Janet Pope Janetbirdope ( View Tweet)
Late-Onset Disease: Different Age, Different Rules?
We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/Txvr62UpWZ
Dr. John Cush RheumNow ( View Tweet)
Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs?
Greek cohort of SSc since 1995
Disease duration 12 yrs,
smoking lung ca group ⬆️58% vs 29%
⬆️dcSSc
⬆️immunosuppression
OR >4X lung ca if dcSSc, IS
Less #DU
#PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc
Links:
Janet Pope Janetbirdope ( View Tweet)
🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity:
💶Cost =barrier in 🇳🇱
⛈️Weather =barrier in 🇹🇷
🧑⚕️HCP support =key in 🇫🇷
🏃Active transport & knowledge =enablers in 🇨🇭
Tailored physical activity interventions needed.
@RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7
Mrinalini Dey DrMiniDey ( View Tweet)
Can RZB deliver in real-world early PsA?
💥 9-month results say yes:
✅ Dactylitis gone in 79%
✅ Enthesitis in 90%
✅ 97% MDs & 88% pts satisfied
Early intervention may pay off.
Abstract POS0304 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
What is new in SpA?
‼️nomenclature change:
🚫AS≠ Ankylosing spondylitis
✅AS= Axial spondyloarthritis
-Helena Marzo-Ortega at #EULAR2025
@RheumNow
Adela Castro AdelaCastro222 ( View Tweet)
About #Multidisciplinarity ...
Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care
#quotes
#EULAR2025
#Invitedspeaker
#outofthebox
@RheumNow
@epirheum https://t.co/RG6xpHejv9
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI
David Liew drdavidliew ( View Tweet)
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases?
A thread 🧵👇🏼
@RheumNow #EULAR2025 https://t.co/KLZN9MvcFy
Aurelie Najm AurelieRheumo ( View Tweet)
Even after having things laid out in a great debate, rheumatologists remain unconvinced by medical cannabis #EULAR2025 @RheumNow https://t.co/xMTvngS5N1
David Liew drdavidliew ( View Tweet)
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis
In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/qi0qHPd06j
Dr. John Cush RheumNow ( View Tweet)
#polyrefractory #RA
=
failed all classes in #rheumatoid #arthritis
+inflammatory #arthritis
Longer disease duration
Late RA Rx
+power Doppler in POCUS
⬆️no refractory
BMI
Fibromyalgia - pain
⬇️SJC, less DAS , rapid X-ray progression
#EULAR2025 @RheumNow #D2T #RA https://t.co/1sPwf3Qa3m
Links:
Janet Pope Janetbirdope ( View Tweet)
